Dr. Ashwin Pachaatt Vinod

A dream that began years ago has finally come true — Dr. Ashwin P Vinod, MBBS, MD (Medicine), DM (Hepatology) it is! Endless gratitude to Dept. of Hepatology, PGIMER & its incredible faculty for shaping my journey. Thank you all for being part of this dream. @HepatologyPGI

The rollout of Lenacapavir, Gilead's twice-yearly HIV-preventative with up to 100% efficacy in trials, is moving forward It's reached 9 countries so far, with 12 more planned – aiming to access 3 million people by 2028

Primary sclerosing cholangitis @TheLancet doi.org/10.1016/S0140-… 👏Excellent review on PSC @EASLnews @ILCAnews @curecc

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies 🔓@HepCommJournal journals.lww.com/hepcomm/fullte… #PBC #Seladelpar #LiverTwitter #LiverX #OpenAccess

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. cell.com/cell-metabolis…

🟣EASL position paper on palliative care in advanced chronic liver disease 🔓#OpenAccess at👉jhep-reports.eu/article/S2589-… #LiverDisease #LiverX #LiverTwitter #LiverHealth

A massive Nature study of 27,885 GLP-1 users just dropped some major news about Ozempic and tirzepatide. Your DNA determines how much weight you lose and how bad the side effects hit. 1 in 3 people see minimal results, and now we know why: (1/9)

Landmark studies on clinically significant portal hypertension and decompensated cirrhosis fg.bmj.com/content/early/… via @KGananandan et al

Great fun writing this article on landmark papers in decomp cirrhosis and CSPH. Thanks @ReibergerThomas and Prof Tsochatzis for being co-authors and @FrontGastro_BMJ for publishing! Check out 👇 doi.org/10.1136/flgast… @EASLedu @BASLedu @BSGTrainees @AASLDtweets #livertwitter

A reminder that in the HALT-IT trial, tranexamic acid did not ⬇️ mortality or bleeding events, but ⬆️ venous thromboembolic events (x2️⃣). Please stop giving TXA for GI bleeding. Doesn’t matter if it’s upper or lower 🩸- doesn’t work but can cause harm ⛔️ thelancet.com/journals/lance…

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in BCLC A HCC and high risk of recurrence @HEP_Journal doi.org/10.1097/HEP.00… 🔎🇫🇷43 pts, NIVOLEP trial 👉ORR 25% after Nivo 👉2yrs OS rate 75% 🧐Not sure whether there is a future for IRI in HCC, but interesting data @EASLedu @myESMO @ILCAnews

FDA Approves FOUNDAYO (orforglipron), an Oral GLP-1 Receptor Agonist, for Weight Loss

I am a big fan of oncology brothers ❤️ , their work significantly supported my growth and continuity in this field, I truly credit them for helping me advance in my oncology career and patients care . youtu.be/1t0iJx4utEM?si… #oncology #medtwitter #oncologybrothers @OncBrothers

Here is the link to our full discussion with @SKamath_MD on #BiliaryTractCancer Treatment Algorithm! #Oncology #Cancer @ClevelandClinic @OncUpdates #OncTwitter #MedX youtu.be/1t0iJx4utEM?si…

This slide by Dr Patrick Kamath Which happiness level are you in ?

Review Finite nucleos(t)ide analog therapy for functional cure in HBeAg-negative chronic hepatitis B: Recent development in the paradigm shift Liaw et al. #LiverX shorturl.at/Q0y39

As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance. A new Practice Guidance update in @HEP_Journal provides evidence-based recommendations on using semaglutide therapy for MASH, including patient selection, comorbidity management, and monitoring strategies. 📗 View the update: bit.ly/4s4QM6A

NEW in @LancetGastroHep: The challenge of defining metabolic dysfunction and alcohol-associated liver disease, with my institute colleague @juanpabloarab #livertwitter #MetALD bit.ly/4cPEyKi

Surviving Sepsis 2026 is here & it's even more loony tunes than I was expecting. They're promoting pre-hospital ABX & preemptive broad-spectrum IV antibiotics for intubated patients. This insane fever dream is an antimicrobial stewardship nightmare. Embarrassment for SCCM.

Large volume fluids then vasopressors then beta agonists for shock. In 2026. This is so low IQ.